From: GPC3 affects the prognosis of lung adenocarcinoma and lung squamous cell carcinoma
Characteristics | Variable | Number of patients | GPC3 expression | Test | P value | |||
---|---|---|---|---|---|---|---|---|
High | Percent (%) | Low | Percent (%) | |||||
Age | ≥ 65 | 310 | 146 | 55.9 | 164 | 53.8 | Wilcoxon | 0.1332 |
 | < 65 | 256 | 115 | 44.1 | 141 | 46.2 |  |  |
Location | Central Lung | 67 | 29 | 39.2 | 38 | 30.9 | Wilcoxon | 0.2896 |
 | Peripheral Lung | 130 | 45 | 60.8 | 85 | 69.1 |  |  |
years_smoked | ≥ 41 | 160 | 105 | 62.5 | 129 | 57.1 | Wilcoxon | 0.5824 |
 | < 41 | 234 | 63 | 37.5 | 97 | 42.9 |  |  |
pathologic_M | M0 | 394 | 1 | 0.4 | 1 | 0.3 | Kruskal | 0.7793 |
 | M1 | 20 | 3 | 1.1 | 2 | 0.6 |  |  |
 | M1a | 2 | 6 | 2.3 | 14 | 4.4 |  |  |
 | M1b | 5 | 176 | 66.7 | 218 | 69.2 |  |  |
 | MX | 158 | 78 | 29.5 | 80 | 25.4 |  |  |
pathologic_N | N0 | 371 | 14 | 5.2 | 3 | 1 | Kruskal | 0.0141 |
 | N1 | 107 | 177 | 65.8 | 194 | 61.6 |  |  |
 | N2 | 87 | 38 | 14.1 | 69 | 21.9 |  |  |
 | N3 | 2 | 39 | 14.5 | 48 | 15.2 |  |  |
 | NX | 17 | 1 | 0.4 | 1 | 0.3 |  |  |
pathologic_T | T1 | 82 | 24 | 8.9 | 25 | 7.9 | Kruskal | 0.0002 |
 | T1a | 49 | 34 | 12.6 | 26 | 8.3 |  |  |
 | T1b | 60 | 34 | 12.6 | 55 | 17.5 |  |  |
 | T2 | 203 | 4 | 1.5 | 16 | 5.1 |  |  |
 | T2a | 89 | 14 | 5.2 | 15 | 4.8 |  |  |
 | T2b | 29 | 91 | 33.7 | 112 | 35.6 |  |  |
 | T3 | 50 | 16 | 5.9 | 34 | 10.8 |  |  |
 | T4 | 20 | 51 | 18.9 | 31 | 9.8 |  |  |
 | TX | 3 | 2 | 0.7 | 1 | 0.3 |  |  |
Radiation therapy | Yes | 69 | 33 | 13.9 | 36 | 13.9 | Wilcoxon | 0.4830 |
 | No | 428 | 205 | 86.1 | 223 | 86.1 |  |  |
Gender | Female | 316 | 110 | 40.7 | 159 | 50.5 | Wilcoxon | 0.0027 |
 | Male | 269 | 160 | 59.3 | 156 | 49.5 |  |  |
Tumor stage | I | 316 | 163 | 61.5 | 153 | 49.2 | Kruskal | 0.0435 |
 | II | 135 | 11 | 4.2 | 17 | 5.5 |  |  |
 | III | 97 | 50 | 18.9 | 85 | 27.3 |  |  |
 | IV | 28 | 41 | 15.5 | 56 | 18 |  |  |